Nateglinide drug data and news

---

SNDA for a Fast-acting Postprandial Hypoglicemic Agent FASTIC ...  Jan 27, 2006
FASTIC Tablet / STARSIS Tablet (generic name: nateglinide*1), a fast-acting postprandial hypoglycemic agent, jontly developed by the companies for the ... - PharmaLive.com (press release),

Ajinomoto, Astellas Pharma Jointly File Application Seeking ...  Jan 31, 2006
Pharma jointly announced on January 27 that they have filed a supplemental New Drug Application (SNDA) for FASTIC Tablet/STARSIS Tablet (nateglinide), a fast ... - Japan Corporate News (press release),

NAVIGATOR Screening Turns up 9,000 People with Undiagnosed ...  Nov 17, 2005
November 17, 2005 --- Researchers say they discovered thousands of undiagnosed diabetics during screening for the massive NAVIGATOR (Nateglinide And Valsartan ... - DG News

NAVIGATOR data presented at American Heart Association's ...  Nov 16, 2005
More about NAVIGATOR and recent screening data The ongoing NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial examines ... - PR Newswire (press release),

NAVIGATOR Data Presented at American Heart Association's ...  Nov 16, 2005
The ongoing NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial examines whether Diovan and/or Starlix(R) (nateglinide ... - PharmaLive.com (press release),

Type 2 diabetes, treatment with Starlix and Metformin results in a ...  Oct 17, 2005
Researchers reported that in a two-year, controlled study people with type 2 diabetes receiving Starlix ( Nateglinide ) in combination with Metformin ... - Xagena.it,

Glimepiride in the medical management of Type 2 diabetes  Oct 23, 2005
...thiazolidinediones (pioglitazone and rosiglitazone), meglitinide analogues (repaglinide), amino acid D-phenylalanine derivatives (nateglinide), and insulin. ... - MedIndia,

Contributions of Basal and Post-Prandial Hyperglycaemia to Micro ...  Aug 12, 2005
...secretion compared with insulin insensitivity was confirmed by Uchino and colleagues, who used the rapid-acting insulin secretagogue, nateglinide, to restore ... - RedNova.com,

Strategies to Prevent Type 2 Diabetes  Aug 12, 2005
...prevention are underway, including DREAM (Diabetes REduction Approaches with ramipril and rosiglitazone Medications); NAVIGATOR (Nateglinide And Valsartan in ... - RedNova.com,

The Broadening Domain of the Metabolic Syndrome  Jul 29, 2005
The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is a multinational, randomized, placebo-controlled, prospective ... - Medscape (subscription)

Ask the internist: Variety of medications can help with diabetes ...  Jul 19, 2005
Meglitinides (Starlix or nateglinide, Prandin or repaglinide): These medicines also cause release of insulin from the pancreas, but very quickly. ... - Billings Gazette

New diabetic drug class shows promise  Mar 25, 2005
There are two only commercially available meglitinides: NovoNordisk’s Repaglinide (Prandin) and Novartis’ Nateglinide (Starlix). ... - Drug Researcher.com,

In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%). Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide. Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.

Glyburide:   In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily. There were no clinically relevant alterations in the pharmacokinetics of either agent.

Metformin:   When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.

Digoxin:   When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.

Warfarin:   When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent. Prothrombin time was not affected.

Diclofenac:   Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.

Nateglinide is highly bound to plasma proteins (98%), mainly albumin. In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding. Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro . However, prudent evaluation of individual cases is warranted in the clinical setting.

Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.

Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.

When these drugs are administered to or withdrawn from patients receiving Starlix, the patient should be observed closely for changes in glycemic control.